UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 52

Sortiert nach

Phase 1 study of M2698, a p70S6K/AKT dual inhibitor, in patients with advanced cancer

Journal of hematology and oncology, 2021-08, Vol.14 (1), p.127-127, Article 127

2021

Volltextzugriff (PDF)

A First-in-Human Phase I Study of Milademetan, an MDM2 Inhibitor, in Patients With Advanced Liposarcoma, Solid Tumors, or Lymphomas

Journal of clinical oncology, 2023-03, Vol.41 (9), p.1714-1724

2023

Volltextzugriff (PDF)

First‐in‐human, phase I study of PF‐06647263, an anti‐EFNA4 calicheamicin antibody–drug conjugate, in patients with advanced solid tumors

International journal of cancer, 2019-10, Vol.145 (7), p.1798-1808

2019

Volltextzugriff (PDF)

Possible case of levofloxacin-induced thrombocytopenia

American journal of health-system pharmacy, 2011-01, Vol.68 (1), p.43-46

2011

Volltextzugriff (PDF)

Intratumoral DNA electroporation induces anti-tumor immunity and tumor regression

Cancer Immunology, Immunotherapy, 2010-03, Vol.59 (3), p.409-417

2010

Volltextzugriff (PDF)

New Options for the Adjuvant Treatment of Cutaneous Melanoma?

Current oncology reports, 2014-11, Vol.16 (11), p.409-409, Article 409

2014

Volltextzugriff (PDF)

Fatal liver failure in a patient on acetaminophen treated with sunitinib malate and levothyroxine

The Annals of pharmacotherapy, 2009-04, Vol.43 (4), p.761

2009

Volltextzugriff (PDF)

New options in the management of intractable ALK(+) metastatic non-small-cell lung cancer

Lung cancer (Auckland), 2014-01, Vol.5 (default), p.35-42

2014

Volltextzugriff (PDF)

Expression of estrogenicity genes in a lineage cell culture model of human breast cancer progression

Breast cancer research and treatment, 2010-02, Vol.120 (1), p.35-45

2010

Volltextzugriff (PDF)

False positive PET scan in patients with treated malignancy following COVID-19 vaccination

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.e18698-e18698

2023

Volltextzugriff (PDF)

Her-2 DNA versus cell vaccine: immunogenicity and anti-tumor activity

Cancer Immunology, Immunotherapy, 2009-05, Vol.58 (5), p.759-767

2009

Volltextzugriff (PDF)

Profiling of targetable aberrations in advanced sarcoma

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.e22559-e22559

2019

Volltextzugriff (PDF)

XMT-1660: A phase 1b trial of a B7-H4 targeted antibody drug conjugate (ADC) in breast, endometrial, and ovarian cancers

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.TPS3154-TPS3154

2023

Volltextzugriff (PDF)

Significant durable response with fianlimab (anti-LAG-3) and cemiplimab (anti-PD-1) in advanced melanoma: Post adjuvant PD-1 analysis

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.9501-9501

2023

Volltextzugriff (PDF)

A phase 1 study of fianlimab (anti-LAG-3) in combination with cemiplimab (anti-PD-1) in patients with advanced melanoma: Poor-prognosis subgroup analysis

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.9548-9548

2023

Volltextzugriff (PDF)

Is a clinical biomarker predictive of outcomes with immune checkpoint inhibitor (ICI) therapy in a phase I patient population

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.e14136-e14136

2019

Volltextzugriff (PDF)

CX-2009, a CD166-directed probody drug conjugate (PDC): Results from the first-in-human study in patients (Pts) with advanced cancer including breast cancer (BC)

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.526-526

2020

Volltextzugriff (PDF)

Clinical results with combination of anti-CD27 agonist antibody, varlilumab, with anti-PD1 antibody nivolumab in advanced cancer patients

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.3007-3007

2017

Volltextzugriff (PDF)

Phase I study combining the aurora kinase A (AURKA) inhibitor alisertib (Ali) with mFOLFOX in gastrointestinal (GI) cancer

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.2593-2593

2017

Volltextzugriff (PDF)

Phase 1/2a study of double immune suppression blockade by combining a CSF1R inhibitor (Pexidartinib/PLX3397) with an anti PD-1 antibody (Pembrolizumab) to treat advanced, solid tumors

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.TPS11618-TPS11618

2016

Volltextzugriff (PDF)

A phase 1b/2 study of ARRY-382, an oral inhibitor of colony stimulating factor 1 receptor (CSF1R), in combination with pembrolizumab (Pembro) for the treatment of patients (Pts) with advanced solid tumors

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.TPS3110-TPS3110

2017

Volltextzugriff (PDF)

A phase 1 study of MDM2 inhibitor DS-3032b in patients with well/de-differentiated liposarcoma (WD/DD LPS), solid tumors (ST) and lymphomas (L)

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.11514-11514

2018

Volltextzugriff (PDF)

Phase 1/2a study of double immune suppression blockade by combining a CSF1R inhibitor (pexidartinib/PLX3397) with an anti PD-1 antibody (pembrolizumab) to treat advanced melanoma and other solid tumors

Journal of clinical oncology, 2016-02, Vol.34 (4_suppl), p.TPS465-TPS465

2016

Volltextzugriff (PDF)

Anti-CD27 agonist antibody varlilumab (varli) with nivolumab (nivo) for colorectal (CRC) and ovarian (OVA) cancer: Phase (Ph) 1/2 clinical trial results

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.3001-3001

2018

Volltextzugriff (PDF)

A phase I study of continuous (Con) and intermittent (Int) AZD2014 plus fulvestrant (F) in patients (pts) with estrogen receptor (ER+) metastatic breast cancer (BC)

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.563-563

2016

Volltextzugriff (PDF)

1 – 25 von 52

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(49)
Mit Volltextzugriff
(46)

Publikationsform

Artikel
(51)
Tagungsberichte
(1)

Sprache

Englisch
(52)
Japanisch
(2)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

14 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Phase 1 study of M2698, a p70S6K/AKT dual inhibitor, in patients with advanced cancer

A First-in-Human Phase I Study of Milademetan, an MDM2 Inhibitor, in Patients With Advanced Liposarcoma, Solid Tumors, or Lymphomas

First‐in‐human, phase I study of PF‐06647263, an anti‐EFNA4 calicheamicin antibody–drug conjugate, in patients with advanced solid tumors

Possible case of levofloxacin-induced thrombocytopenia

Intratumoral DNA electroporation induces anti-tumor immunity and tumor regression

New Options for the Adjuvant Treatment of Cutaneous Melanoma?

Fatal liver failure in a patient on acetaminophen treated with sunitinib malate and levothyroxine

New options in the management of intractable ALK(+) metastatic non-small-cell lung cancer

Expression of estrogenicity genes in a lineage cell culture model of human breast cancer progression

False positive PET scan in patients with treated malignancy following COVID-19 vaccination

Her-2 DNA versus cell vaccine: immunogenicity and anti-tumor activity

Profiling of targetable aberrations in advanced sarcoma

XMT-1660: A phase 1b trial of a B7-H4 targeted antibody drug conjugate (ADC) in breast, endometrial, and ovarian cancers

Significant durable response with fianlimab (anti-LAG-3) and cemiplimab (anti-PD-1) in advanced melanoma: Post adjuvant PD-1 analysis

A phase 1 study of fianlimab (anti-LAG-3) in combination with cemiplimab (anti-PD-1) in patients with advanced melanoma: Poor-prognosis subgroup analysis

Is a clinical biomarker predictive of outcomes with immune checkpoint inhibitor (ICI) therapy in a phase I patient population

CX-2009, a CD166-directed probody drug conjugate (PDC): Results from the first-in-human study in patients (Pts) with advanced cancer including breast cancer (BC)

Clinical results with combination of anti-CD27 agonist antibody, varlilumab, with anti-PD1 antibody nivolumab in advanced cancer patients

Phase I study combining the aurora kinase A (AURKA) inhibitor alisertib (Ali) with mFOLFOX in gastrointestinal (GI) cancer

Phase 1/2a study of double immune suppression blockade by combining a CSF1R inhibitor (Pexidartinib/PLX3397) with an anti PD-1 antibody (Pembrolizumab) to treat advanced, solid tumors

A phase 1b/2 study of ARRY-382, an oral inhibitor of colony stimulating factor 1 receptor (CSF1R), in combination with pembrolizumab (Pembro) for the treatment of patients (Pts) with advanced solid tumors

A phase 1 study of MDM2 inhibitor DS-3032b in patients with well/de-differentiated liposarcoma (WD/DD LPS), solid tumors (ST) and lymphomas (L)

Phase 1/2a study of double immune suppression blockade by combining a CSF1R inhibitor (pexidartinib/PLX3397) with an anti PD-1 antibody (pembrolizumab) to treat advanced melanoma and other solid tumors

Anti-CD27 agonist antibody varlilumab (varli) with nivolumab (nivo) for colorectal (CRC) and ovarian (OVA) cancer: Phase (Ph) 1/2 clinical trial results

A phase I study of continuous (Con) and intermittent (Int) AZD2014 plus fulvestrant (F) in patients (pts) with estrogen receptor (ER+) metastatic breast cancer (BC)

Suchergebnisse filtern